Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Wegovy and Saxenda are the two GLP-1 medications approved specifically for weight management. That distinction matters, because most GLP-1 drugs people take for weight loss were actually approved for diabetes and are being used off-label.
These two were not. They were designed and licensed for this purpose, at doses chosen for it. Comparing them is a fair fight, and one trial compared them head to head.
What each one is
Wegovy is semaglutide at 2.4 mg, injected once weekly.
Saxenda is liraglutide at 3.0 mg, injected once daily.
Both are made by Novo Nordisk. Both mimic GLP-1 (glucagon-like peptide-1, the hormone your gut releases after eating that tells your brain you have had enough).
The related products cause endless confusion, so it is worth stating plainly. Ozempic is semaglutide at diabetes doses. Victoza is liraglutide at diabetes doses. Wegovy and Saxenda are the weight management versions of those same two molecules.
The head-to-head result
STEP 8, published in JAMA in 2022, randomly assigned adults with overweight or obesity but without diabetes to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg, and followed them for 68 weeks.
Semaglutide produced significantly greater weight loss. The difference was large enough to matter clinically, not just to reach statistical significance.
The separate trials point the same way. The SCALE trial, published in the New England Journal of Medicine, recorded an average 8.4 kg loss on liraglutide 3.0 mg over 56 weeks against 2.8 kg on placebo. STEP 1 recorded an average 14.9 percent body weight reduction on semaglutide 2.4 mg over 68 weeks.
STEP 8 is the evidence that counts, because it removed the differences in population and design that make cross-trial comparison unreliable.
Dosing burden
| Wegovy | Saxenda | |
|---|---|---|
| Frequency | Weekly | Daily |
| Injections per year | 52 | 365 |
| Titration length | 16 weeks | 5 weeks |
| Starting dose | 0.25 mg | 0.6 mg |
| Target dose | 2.4 mg | 3.0 mg |
Seven times the injections is the difference that decides this for many people.
Real-world adherence data on daily injectables is poor. People manage the first month or two, then the daily routine becomes the reason they stop. Since GLP-1 appetite suppression depends on consistent drug levels, missed doses cost you results directly.
Wegovy escalates more slowly, over roughly 16 weeks. That is a longer wait to reach full effect, but it generally means gentler side effects along the way. Saxenda reaches full dose in five weeks, which some people find abrupt.
Side effects
Both cause the same category of effects, because both work by slowing stomach emptying.
Nausea leads for both, affecting roughly 40 percent of users. Vomiting, diarrhoea and constipation follow.
The patterns differ. Saxenda's daily dosing tends to produce steadier low-level effects. Wegovy's weekly dosing concentrates them into the days after each injection for some people, then eases.
In STEP 8, gastrointestinal side effects were common on both. Neither emerged with a clean tolerability advantage.
Serious risks are shared across the class. Pancreatitis, gallbladder disease and the medullary thyroid carcinoma contraindication apply equally. Neither is used during pregnancy or breastfeeding.
The stopping rules differ
This is a practical point people miss.
Saxenda has a defined checkpoint. If you have not lost at least 4 percent of your starting weight after 16 weeks at the full 3.0 mg dose, guidance is to stop, because you are unlikely to respond.
Wegovy's assessment point comes later, reflecting its longer titration.
Both rules exist for the same reason. A minority of people simply do not respond to GLP-1 appetite suppression, and continuing an expensive medication that is not working serves nobody.
Cost
Neither is cheap, and both are expensive in ways that compound.
Saxenda uses more drug per week at daily dosing, so pens deplete faster. Wegovy's weekly pens last longer per unit but the drug itself is priced higher.
In practice the monthly cost of both lands in a similar bracket, and both need to be sustained across many months for the trial results to apply. STEP 8 measured its results at 68 weeks. That is the commitment being compared, not a single month.
Availability in Pakistan
Neither Wegovy nor Saxenda is registered for sale in Pakistan. Both reach the country through import or informal channels, both need refrigeration, and both are exposed to exchange rate movement and global supply shortages.
Semaglutide in particular has faced repeated worldwide shortages driven by weight loss demand.
This changes what the comparison is actually about. A drug with better trial results that you cannot obtain for sixteen consecutive weeks will underperform a lesser option you can complete. Continuity is not separate from efficacy here. It determines it.
That is the reason locally registered alternatives exist in this market. The METASLIM™ 8-week program delivers GLP-1 pathway appetite support as sublingual drops held under the tongue, with a physician reviewing every order before it ships. It is a physician-reviewed supplement rather than pharmaceutical semaglutide or liraglutide, and it should not be presented as equivalent to either. What it removes is the injection, the cold chain, and the dependence on an import route that keeps breaking.
If you are not sure which category you fall into, take our weight loss quiz for a guided view of your options. Our detailed Saxenda guide and Saxenda vs Ozempic comparison go deeper on the liraglutide side.
The verdict
On weight loss, Wegovy wins clearly. STEP 8 settled it directly.
On convenience, Wegovy wins again. Fifty-two injections against three hundred and sixty-five is not close.
On tolerability, they are comparable with different patterns.
On cost, they are broadly similar once you account for how fast Saxenda pens deplete.
On availability in Pakistan, neither is reliable, and that is the factor that decides it for most people reading this.
Start the 8-week program if you want a supervised option you can actually complete.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.